80,000 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Acquired by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB bought a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $2,522,000.

Other hedge funds also recently bought and sold shares of the company. Handelsbanken Fonder AB boosted its stake in shares of Astrana Health by 4.7% during the 4th quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company’s stock worth $281,000 after purchasing an additional 400 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Astrana Health by 1.1% during the fourth quarter. Swiss National Bank now owns 88,444 shares of the company’s stock worth $2,789,000 after purchasing an additional 1,000 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Astrana Health in the fourth quarter valued at $40,000. Pictet Asset Management Holding SA boosted its stake in Astrana Health by 21.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 7,075 shares of the company’s stock worth $223,000 after buying an additional 1,273 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Astrana Health by 108.4% during the 4th quarter. KBC Group NV now owns 2,530 shares of the company’s stock valued at $80,000 after acquiring an additional 1,316 shares during the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Bank of America cut their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Macquarie upgraded Astrana Health to a “hold” rating in a report on Monday, December 16th. Stifel Nicolaus reduced their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Truist Financial dropped their price objective on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Finally, Barclays initiated coverage on shares of Astrana Health in a research report on Tuesday. They set an “equal weight” rating and a $36.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $30.07 on Friday. The firm has a 50-day moving average of $33.17 and a two-hundred day moving average of $41.24. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market cap of $1.51 billion, a P/E ratio of 23.13, a PEG ratio of 1.37 and a beta of 1.30. Astrana Health, Inc. has a 1-year low of $23.12 and a 1-year high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. On average, research analysts expect that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.